Tilatamig samrotecan

Tilatamig samrotecan (AZD9592) is an antibody-drug conjugate (ADC) used to deliver topoisomerase I inhibitors (TOP1i), targeting the epidermal growth factor receptor (EGFR) and c-MET, with anti-tumor activity. Tilatamig samrotecan (AZD9592) can induce DNA double-strand breaks, increase the expression of pRAD50 and γH2AX, and inhibit the growth of non-small cell lung cancer[1][2].

Product Specifications

Product Name Alternative

AZD9592

UNSPSC

12352203

Target

DNA/RNA Synthesis; Topoisomerase

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

[Tilatamigsamrotecan]

References & Citations

[1]Lara McGrath, et al. Abstract 5737: Evaluation of the relationship between target expression and in vivo anti-tumor efficacy of AZD9592, an EGFR/c-MET targeted bispecific antibody drug conjugate. Cancer research. (2023) 83 (7_Supplement) : 5737.|[2]Kinsley Wang, et al. Anti-MET Antibody Therapies in Non-Small-Cell Lung Cancer: Current Progress and Future Directions. Antibodies (Basel) . 2024 Oct 18;13 (4) :88.